Shire PLC (LON:SHP) had its price target cut by Goldman Sachs Group, Inc. (The) from GBX 6,800 ($88.08) to GBX 6,400 ($82.90) in a note issued to investors on Wednesday, Marketbeat Ratings reports. The brokerage currently has a “conviction-buy” rating on the biopharmaceutical company’s stock. Goldman Sachs Group, Inc. (The)’s target price would suggest a potential upside of 51.19% from the company’s previous close.

Other equities research analysts have also recently issued reports about the stock. Deutsche Bank AG reiterated a “buy” rating on shares of Shire PLC in a research report on Tuesday, March 28th. Societe Generale reiterated a “buy” rating and set a GBX 6,200 ($80.31) price objective on shares of Shire PLC in a research report on Thursday, March 23rd. Liberum Capital reiterated a “buy” rating and set a GBX 5,500 ($71.24) price objective on shares of Shire PLC in a research report on Thursday, March 9th. Citigroup Inc. reiterated a “buy” rating on shares of Shire PLC in a research report on Wednesday, April 12th. Finally, Berenberg Bank reiterated a “buy” rating on shares of Shire PLC in a research report on Wednesday, April 12th. One analyst has rated the stock with a sell rating, one has given a hold rating, fourteen have assigned a buy rating and one has given a strong buy rating to the stock. Shire PLC has an average rating of “Buy” and an average target price of GBX 6,005.60 ($77.79).

Shares of Shire PLC (SHP) traded down 0.12% during trading on Wednesday, hitting GBX 4233.00. 1,482,989 shares of the stock were exchanged. Shire PLC has a 52 week low of GBX 2,707.19 and a 52 week high of GBX 5,377.00. The firm’s 50 day moving average price is GBX 4,526.50 and its 200-day moving average price is GBX 4,615.89. The stock’s market cap is GBX 38.27 billion.

TRADEMARK VIOLATION NOTICE: This piece was reported by American Banking News and is the property of of American Banking News. If you are reading this piece on another site, it was illegally copied and republished in violation of United States & international trademark and copyright legislation. The original version of this piece can be viewed at https://www.americanbankingnews.com/2017/07/03/shire-plc-lonshp-price-target-cut-to-gbx-6400-by-analysts-at-goldman-sachs-group-inc-the.html.

In other Shire PLC news, insider Dominic Blakemore acquired 152 shares of the company’s stock in a transaction on Friday, June 30th. The shares were purchased at an average cost of GBX 4,255 ($55.12) per share, with a total value of £6,467.60 ($8,377.72).

About Shire PLC

Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company’s segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases.

Analyst Recommendations for Shire PLC (LON:SHP)

Receive News & Ratings for Shire PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire PLC and related companies with MarketBeat.com's FREE daily email newsletter.